International product revenues totaled $17.8 million in the reported quarter, up 29% year over year (up 32.9% at adjusted constant currency). During the first quarter, the company delivered more than 37,580 Oncotype DX test results, up 15.9% year over year. Margin Trend Genomic Health's gross margin expanded 460 basis points (bps) year over year to 84.4% in the first quarter. The company also saw a 2.5% escalation in operating expenses to $80.2 million on an 8.6% rise in selling and marketing expenses to $45.3 million and a 0.5% increase in general and administrative expenses to $19.8 million. However, research and development expenses declined 10.4% to $15.1 million. In the reported quarter, Genomic Health's operating profit came in at $11.5 million against the year-ago operating loss of $4.4 million. Operating margin expanded a huge 1535 bps to 10.6% in the quarter.